x
Japan Cell and Gene Therapy Market Overview
Market Size and Growth
Base Year: 2024
Historical Years: 2019-2024
Forecast Years: 2025-2033
Market Size in 2024: USD 727 Million
Market Forecast in 2033: USD 2,016 Million
Market Growth Rate: 12% (2025-2033)
According to the latest report by IMARC Group, the Japan cell and gene therapy market size reached USD 727 million in 2024. Looking forward, IMARC Group expects the market to reach USD 2,016 million by 2033, exhibiting a CAGR of 12% from 2025 to 2033.
Japan Cell and Gene Therapy Industry Trends and Drivers
Japan's market for cellular and gene therapy products and services is moving forward, as early launches turn into other, broader levels of clinical integration, thanks to well-defined pathways for regenerative medical products with device like approval, robust expedite review procedures, and manageable pricing scaffolding that turns good data into tangible access. The PMD act provides a conditional time-restricted approval pathway for regenerative products so they can be marketed sooner, with some form of post approval verification, and established priority pathways, such as Sakigake, and structured scientific consultations remove uncertainty and shorten time to decision for products that meet clinically recognized high need requirements. Facilities and payers more frequently want carefully designed evidence packages that include clearly defined endpoints, long term follow up, and risk management plans; not surprisingly, we see developers investing in localized clinical and pre-clinical protocols and logistics for both autologous and allogeneic cellular and gene therapy products across oncology, cardiovascular, neurological, and metabolic indications.
Manufacturing capacity is being expanded through large investments from CDMOs and government assisted programs aimed at supporting domestic capacity for better security of domestic production and domestic cold chain capacity, further strengthening resilience of domestic clinical supply and commercial scale up. Recent policy updates clarify oversight of in vivo gene therapy design while reinforcing committee reviews for conflicting interests while upholding standards for data. This also raises the stakes for quality while maintaining a transparent application to review and eventual National Health Insurance listing. Sponsors that combine and implement practices that keep patients active in the protocol development will enhance quality, while "building evidence", the appetite for transparency of all methodical processes will foster confidence of evidence generation support while keeping those stakeholder engagements informed and developing individualized evidence boosting in clinical settings on behalf of the sponsor.
Request for a Sample Copy of the Report: https://www.imarcgroup.com/japan-cell-gene-therapy-market/requestsample
Japan Cell and Gene Therapy Market Segmentation
The market report offers a comprehensive analysis of the segments, highlighting those with the largest Japan cell and gene therapy market share. It includes forecasts for the period 2025-2033 and historical data from 2019-2024 for the following segments:
Therapy Type Insights:
Cell Therapy
Gene Therapy
Indication Insights:
Delivery Mode Insights:
End User Insights:
Regional Insights:
Ask Analyst for Sample Report: https://www.imarcgroup.com/request?type=report&id=17931&flag=C
Competitive Landscape
The report offers an in-depth examination of the competitive landscape. It includes a thorough competitive analysis encompassing market structure, key player positioning, leading strategies for success, a competitive dashboard, and a company evaluation quadrant. Additionally, the report features detailed profiles of major companies in the Japan cell and gene therapy industry.
Key Highlights of the Report:
Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact
Street: 563-13 Kamien
Area: Iwata
Country: Japan
Postal Code: 4380111
Email: sales@imarcgroup.com
